Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
IPO Year: 2020
Exchange: NASDAQ
Website: reparerx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/9/2023 | $11.00 → $16.00 | Hold → Buy | Stifel |
| 2/3/2023 | $28.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/6/2023 | $28.00 | Overweight | CapitalOne |
| 4/12/2022 | $11.00 | Buy → Hold | Stifel |
| 3/17/2022 | $43.00 | Buy | Goldman |
| 9/23/2021 | $48.00 | Buy | Stifel |
| 9/13/2021 | $54.00 | Buy | HC Wainwright & Co. |
| 8/16/2021 | $45.00 → $47.00 | Overweight | Morgan Stanley |
| 6/28/2021 | $46.00 | Buy | Guggenheim |
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
3 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
8-K - Repare Therapeutics Inc. (0001808158) (Filer)
SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
8-K - Repare Therapeutics Inc. (0001808158) (Filer)
424B5 - Repare Therapeutics Inc. (0001808158) (Filer)
10-Q - Repare Therapeutics Inc. (0001808158) (Filer)
8-K - Repare Therapeutics Inc. (0001808158) (Filer)
8-K - Repare Therapeutics Inc. (0001808158) (Filer)
EFFECT - Repare Therapeutics Inc. (0001808158) (Filer)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13D - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). Repare also announced its intention to seek partnering opp
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first recipient of a personalized mRNA cancer vaccine, training her immune system to target cancer cells and marking a significant step toward more precise, less toxic treatments. These breakthroug
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer Institute (NCI), part of the US National Institutes of Health. "This partnership with the CTEP allows the research community to investigate the full clinical potential of camonsertib more easily and we believe it will provide additional clinical development catalysts for the program," said Lloyd M. Segal, President and Chief
On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational trial in 2025 Presented updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Dosed first patient in Phase 1 POLAR trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and in combination with the PARP inhibitor, olaparib Presented first-in-human data highlighting the clinical benefits of camonsertib in combination with radiotherapy at the ASTRO annual meeting Repare Therapeutics
Data presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial treating patients with the combination of lunresertib, a first-in-class PKMYT1 inhibitor, and camonsertib, a potential best-in-class oral small molecule ATR inhibitor (lunre+camo). Lunre+camo in the MYTHIC clinical trial (NCT04855656) previously demonstrated promising clinical activity in molecularly selected patients across multiple
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's Phase 1 (POLAR) clinical trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. RP-3467 is Repare's fourth clinical program. "RP-3467, our potential best-in-class Polθ ATPase inhibitor, has demonstrated highly compelling preclinical results, including complete and durable tumor regressions in combination with olaparib, the leading PARP inhibitor, with no additive toxicities. This combination is designed to meaningfully imp
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported data highlighting the clinical benefits of camonsertib, a potential best-in-class oral small molecule ATR inhibitor, combined with palliative radiation for the treatment of metastatic tumors harboring an ataxia-telangiectasia-mutated (ATM) mutation. These data from a clinical trial conducted in collaboration with investigators at Memorial-Sloan Kettering Cancer Center were presented at the American Society for Radiation Oncology (ASTRO) annual meeting in Washington, DC by Nancy Lee, MD, FASTRO, Radiation Oncologist & Early Drug Development Specialist, Memo
Data presented at AACR's Ovarian Cancer Research Symposium confirm that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7 or PP2R1A mutations carry poor prognosis Significant survival disparities were identified in patients harboring lunresertib- and camonsertib-sensitizing biomarkers, including CCNE1 amplifications or mutations in FBXW7 or PPP2R1A Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, presented new data on Friday highlighting the impact of alterations in FBXW7, PPP2R1A and CCNE1 in patients with metastatic ovarian and endometrial cancers based on an analysis in approximately 2,000 patients f
Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously
Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously
CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00
Stifel downgraded Repare Therapeutics from Buy to Hold and set a new price target of $11.00
Goldman resumed coverage of Repare Therapeutics with a rating of Buy and set a new price target of $43.00
Stifel initiated coverage of Repare Therapeutics with a rating of Buy and set a new price target of $48.00
HC Wainwright & Co. initiated coverage of Repare Therapeutics with a rating of Buy and set a new price target of $54.00
Morgan Stanley reiterated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $47.00 from $45.00 previously
Guggenheim initiated coverage of Repare Therapeutics with a rating of Buy and set a new price target of $46.00
Morgan Stanley reiterated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $45.00 from $41.00 previously
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, May 31, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that
RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radioligand therapy (RLT) and chemotherapy Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024 Repare to host conference call and webcast today at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development progra
Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcast to discuss latest data from its preclinical programs and overall pipeline, November 15th, 2023 at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023. "We substantially advanced our pipeline during the third quarter, particularly our Phase
Event to be webcast live on Wednesday, November 15 at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time. Conference Call and Webcast Details: To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live webcast will be ava
Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with heavily pre-treated gynecologic tumors, including endometrial, ovarian and cervical, at the preliminary recommended phase 2 dose Encouraging safety and tolerability profile observed as monotherapy and in combination with camonsertib Repare to host conference call and webcast today at 5:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported
Conference call and live webcast on Friday, October 13, 2023 at 5:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to share initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial that will be presented in a plenary session at the upcoming AACR-NCI-EORTC conference, being held October 11-15, 2023 in Boston, MA. The data that will be presented at AACR-NCI-EORTC will be based on a later cutoff date than what is included in the abstracts, which are released on Wednesday, October 4, 2023 at 12:00 p.m. ET. Repare's executive ma
Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) synthetic lethal inhibitor in clinical development for the treatment of molecularly selecte
Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales Repare to host conference call today at 5:00 p.m. EDT Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for
Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2
Repare Therapeutics Inc., (NASDAQ:RPTX), ("Repare", or "the Company"), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company's EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company's common shares. The award was approved by the Compensation Committee of the Company's Board of Directors and was granted outside of the Company's 2020 Equity Incentive Plan, with a grant date of May 18, 2023, as an inducement material to Mr. Belanger entering into employment with Repare, in accordance with Nasdaq Listing Rule 5635(c)(4). The st
Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile Company on track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023 Announced the appointment of Susan Molineaux, Ph.D., and departure of Jerel Davis, Ph.D. on our Board of Directors, as well as the addition of Daniel Belanger to the senior leadership team Repare Therapeutics Inc. ("Repare" or the "Company") (NA
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2023. Concurrent with Dr. Molineaux's appointment as of the date of the annual meeting, Jerel Davis, Ph.D., Managing Director at Versant Ventures and a founding member of Repare's Board of Directors, will step down from the Board. "On behalf of the Company and our Board of Directors, I want to thank Jerel for his service and partnership that have been instrumental in building Repare into the leadi
Former CCO of Y-mAbs Therapeutics brings 20 years of pharma and biotech commercial leadership Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development. "We are excited to welcome Phil to Repare as we are looking forward to key catalysts for RP-3500 and RP-6306 in 2022. 2022 will be an important year for us as we continue to build Repare into the leading precision oncology company delivering synthetic lethality medicines that meaningfully improve the lives of cancer patients," said Lloyd M. Segal, President and Chief Executive Of
Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company's Board. "It is my pleasure to welcome Tom to our Board as our new Chairman," said Repare President and CEO Lloyd M. Segal. "Tom brings a wealth of experience in developing and launching innovative oncology drugs and in leading edge mo
Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors. Dr. Koehler is a board-certified hematologist and oncologist with more than 20 years of pharmaceutical and biotech oncology experience in clinical development, including senior roles at Pfizer where she led the development of Ibrance® (palbociclib) and contributed to the strategic direction of the oncology portfolio. "We are extremely pleased to welcome Maria to our Board of Directors at this important next stage